Expertise in
16
conditions

Emmanuel K. Gyan

Tours, FR 
Expertise in
16
conditions
Tours, FR 

Overview

Emmanuel Gyan practices practicing medicine in Tours, France.

Mr. Gyan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS), B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 176 peer reviewed articles and participating in 12 clinical trials.

Gender

Male

Locations

Tours, France
Other Locations
Montpellier, France
Rennes, France
Toulouse, France
Angers, 49033, France
CHU Lyon Sud, Hospices Civils de Lyon
Pierre-la-treiche, France
Nantes, France
Val-de-la-haye, France
CHU Dijon Bourgogne
Dijon, France
Paris, France
CHU Grenoble Alpes
Grenoble, France
Pessac-sur-dordogne, France
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Ibrutinib
Study Phase: Phase 1/Phase 2
QUALHYBOM : Therapeutic Communication Associated With Local Anesthesia Versus Local Anesthesia During Bone Marrow Biopsy: Clinical, Controlled, Randomized, Multicenter Study
QUALHYBOM : Therapeutic Communication Associated With Local Anesthesia Versus Local Anesthesia During Bone Marrow Biopsy: Clinical, Controlled, Randomized, Multicenter Study
Enrollment Status: Completed
Publish Date: June 26, 2025
Intervention Type: Other, Drug
Study Phase: Not Applicable
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
Enrollment Status: Terminated
Publish Date: April 28, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

176 Total Publications

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.
Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.
Journal: Haematologica
Published: June 02, 2026

Frequently Asked Questions about Emmanuel K. Gyan

Is Emmanuel K. Gyan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Emmanuel K. Gyan is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emmanuel K. Gyan participate in research or clinical trials?

Yes. Emmanuel K. Gyan has published 176 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Emmanuel K. Gyan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gyan's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile